

ERRATUM

Open Access



# Erratum to: A new co-ultramicrosized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

Irene Paterniti<sup>1</sup>, Daniela Impellizzeri<sup>1</sup>, Rosanna Di Paola<sup>1</sup>, Michele Navarra<sup>2</sup>, Salvatore Cuzzocrea<sup>1</sup> and Emanuela Esposito<sup>1\*</sup>

## Erratum

The authors would like to issue an erratum for this article [1] and declare the following competing interests, which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.

## Notes

The present study provides an important advance over an earlier report in which almitoylethanolamide alone was used [2], in that the co-ultramicrosized almitoylethanolamide/luteolin composite demonstrates improved potency by an approximate order of magnitude.

## Acknowledgements

We wish to thank Prof. Ernesto Reverchon, Department of Industrial Engineering, University of Salerno, Italy, for his expertise regarding the measurement of micronized/ co-ultramicrosized PEA particle size and energy. Prof. Reverchon is full professor in Chemical Engineering and is the head of the SCF Research Group operating at the University of Salerno, Italy. In the experiments performed in our article [1] Prof. Reverchon only evaluated, during the studies supported by European grants PON01\_02512, the electron microscopy structure of micronized/co-ultramicrosized PEA particles. These studies were not sponsored by Epitech group.

## Competing interests

Dr. Salvatore Cuzzocrea, researcher on the study team, is co-inventor on patent WO2013121449 A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing Nacylethanolamines useable in the therapy of inflammatory diseases. Moreover, Dr. Cuzzocrea is also a co-inventor with Epitech group on the following patents: 1. EP 2 821 083 2. MI2014 A001495 3. 102015000067344 No other authors declare competing interests.

## Ethical approval

The study [1] was approved by the University of Messina Animal Care Review Board: protocol number 8/U-apr 16.

\* Correspondence: [eesposito@unime.it](mailto:eesposito@unime.it)

<sup>1</sup>Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 98166 Messina, Italy

## Author details

<sup>1</sup>Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 98166 Messina, Italy.

<sup>2</sup>Pharmaco-Biological Department, University of Messina, Viale Annunziata, 98100 Messina, Italy.

Received: 23 May 2016 Accepted: 23 May 2016

Published online: 31 May 2016

## References

1. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new coultramicrosized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. *J Neuroinflammation*. 2013;10:91. doi:10.1186/1742-2094-10-91.
2. Esposito E, Paterniti I, Mazzone E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. *Brain Behav Immun*. 2011;25:1099–112. doi:10.1016/j.bbi.2011.02.006.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

